This model consisted of markers that have been reported previously, e.g. itga4, thbd, vav3-as1 and a few novel ones, including kcnj12, znf132, and sfmbt2. In this study, we evaluated the performance of these methylation markers in the plasma cohort, and further refined the methylation model for the application in CRC early detection. This evidence concerns the gene SFMBT2 and colorectal carcinoma.